Long-term dasatinib supported in CML

Dasatinib has durable efficacy and manageable toxicity in the long-term treatment of patients with chronic-phase chronic myeloid leukaemia that is resistant or intolerant to imatinib, shows final analysis of the CA180-034 trial.
Source: MedWire News - Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news